In this study, investigators assessed the cost-effectiveness of using high-dose intravenous proton pump inhibitors in the American and Canadian health care settings.
The team used a validated decision model which included patients with bleeding ulcers who had undergone successful endoscopic hemostasis.
|Results were robust across a wide range of clinically relevant assumptions.|
|Alimentary Pharmacology and Therapeutics|
The team determined probabilities from the literature, and charges and lengths of stay from national databases.
A third-party payer perspective was adopted over a 30-day time horizon.
The team found that rebleeding rates were 6% for patients who received high-dose intravenous proton pump inhibition, compared with 23% for patients who did not.
The investigators calculated the hospitalization costs for patients with and without re-bleeding as US$11,802 and US$7993, and CAN$5220 and CAN$2696, respectively.
They established that high-dose intravenous proton pump inhibition was an effective and economic strategy.
The team found that the cost-effectiveness ratios for the use or non-use of high-dose intravenous proton pump inhibition were US$9112 and US$11,819 (CAN$3293 and CAN$4284), respectively.
Furthermore, the team determined that the results were robust across a wide range of clinically relevant assumptions.
Dr Barkun's team concluded, "High-dose intravenous proton pump inhibition for 3 days is…effective and less costly than not doing so for patients with bleeding ulcers after successful endoscopic hemostasis".